Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEyePoint, Inc

EyePoint, Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3601 USD 0.00 ( 0.03%)
Last update at 2026-11-09T15:42:00Z
VOLUME
860444
Market Cap
315.54M

Momentum Score

…

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.35
Low
0.37
High
52 Week Price Range
3.63
Low
19.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

EyePoint, Inc. is a specialty ophthalmic pharmaceutical company developing and commercializing sustained‑release and injectable therapies for retinal and other intraocular diseases. Long‑term growth could be supported by commercialization of marketed products, progress in the clinical pipeline and expansion of distribution and reimbursement, and investors may find the company attractive for its niche position in long‑acting ocular therapies and potential for recurring revenue.
Principal risks are dependence on a small product set, clinical and regulatory uncertainty for pipeline programs, competition from larger ophthalmic companies and possible need for additional financing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.36
Dividend Yield
-
Revenue TTM
2.79M
Revenue Per Share
0.03
Gross Profit TTM
-257.47M
Debt / Equity
0.07
ROE
-148.70%
Net Debt
-81.05M
ROCE
-74.45%
Diluted EPS TTM
-3.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -231.68M -130.78M -70.71M -102.25M -58.42M
Net income -231.96M -130.87M -70.80M -124.51M -63.91M
Selling general administrative 51.61M 52.36M 40.10M 34.82M 25.57M
Selling and marketing expenses 0.09M 0.13M 11.69M 25.51M 27.50M
Gross profit 29.30M 39.56M 41.39M 33.08M 28.76M
Reconciled depreciation 2.31M 1.54M 0.46M 2.45M 2.77M
Ebit - -130.77M -73.66M -78.94M -55.28M
Ebitda -243.43M -129.23M -73.20M -74.76M -52.52M
Depreciation and amortization - 1.54M 0.46M 4.18M 2.75M
Non operating income net other - - - 0.57M 2.36M
Operating income -243.43M -145.85M -73.66M -78.94M -55.28M
Other operating expenses 274.81M 189.13M 119.68M 120.34M 92.22M
Interest expense 0.03M 0.01M 1.25M 3.19M 5.50M
Tax provision 0.28M 0.09M 0.08M 0.00M -
Interest income 11.78M 15.09M 6.95M 2.13M 0.29M
Net interest income 11.75M 15.07M 5.70M -1.06M -5.21M
Non recurring - - - 20.70M -
Income tax expense 0.28M 0.09M 0.08M 22.26M 5.50M
Total revenue 31.37M 43.27M 46.02M 41.40M 36.94M
Total operating expenses 272.74M 185.41M 115.05M 112.02M 84.04M
Cost of revenue 2.07M 3.71M 4.63M 8.33M 8.18M
Total other income expense net 11.75M 15.07M 2.95M -23.32M -3.14M
Net income from continuing ops -231.96M -130.87M -70.80M -102.25M -58.42M
Net income applicable to common shares - - - -102.25M -58.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 364.00M 418.46M 355.18M 180.36M 263.37M
Intangible assets - - - - 22.75M
Other current assets 20.11M 9.48M 9.04M 9.86M 4.22M
Total liab 57.88M 81.96M 88.86M 83.99M 78.99M
Total stockholder equity 306.11M 336.50M 266.32M 96.37M 184.38M
Deferred long term liab - - - 13.56M 14.56M
Other current liab 2.14M 19.54M 17.60M 16.94M 14.42M
Common stock 1410.13M 0.07M 0.05M 766.93M 752.64M
Capital stock 0.08M 0.07M 0.05M 0.03M 0.03M
Retained earnings -1104.98M -873.02M -742.15M -671.35M -569.10M
Other liab - - - 14.16M 16.91M
Other assets - - - 0.15M 0.63M
Cash 101.82M 99.70M 281.26M 95.63M 178.59M
Total current liabilities 37.02M 49.05M 63.26M 34.54M 23.66M
Current deferred revenue - 17.78M 38.59M 1.21M 1.07M
Net debt -81.05M -77.85M -275.79M -49.86M -140.17M
Short term debt - 1.25M 0.56M 10.47M 0.78M
Short long term debt - - - 10.47M -
Short long term debt total 20.77M 21.86M 5.47M 45.77M 38.42M
Other stockholder equity - 1208.42M 1007.56M 766.90M 752.60M
Property plant equipment - - - 1.36M 2.25M
Total current assets 328.65M 383.31M 344.80M 172.81M 237.75M
Net tangible assets - - - 96.37M 161.63M
Short term investments 204.26M 271.21M 49.79M 48.93M 32.97M
Net receivables 0.65M 0.61M 0.81M 15.50M 18.35M
Long term debt - - - 29.31M 36.56M
Inventory 1.81M 2.31M 3.91M 2.89M 3.62M
Accounts payable 34.88M 11.72M 6.50M 5.92M 7.38M
Accumulated other comprehensive income 0.96M 1.03M 0.86M 0.79M 0.84M
Common stock total equity - - - 0.03M 0.03M
Retained earnings total equity - - - -671.35M -569.10M
Non currrent assets other 15.12M 5.98M 0.15M 1.51M 0.63M
Non current assets total 35.34M 35.16M 10.38M 7.55M 25.63M
Capital lease obligations 20.77M 21.86M 4.91M 6.56M 2.64M
Long term debt total - - - 29.31M 36.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 71.70M -219.35M -3.31M -15.12M -32.97M
Change to liabilities - - - 1.20M 7.54M
Total cashflows from investing activities 68.58M -219.35M - -17.27M -33.12M
Net borrowings -0.10M -0.10M - -0.65M -0.15M
Total cash from financing activities 173.65M 164.02M 187.07M -0.69M 216.90M
Change to operating activities - - - 0.07M -0.03M
Net income -231.96M -130.87M -70.80M -102.25M -58.42M
Change in cash 2.12M -181.56M 185.63M -82.96M 133.68M
Begin period cash flow 99.85M 281.41M 95.63M 178.74M 45.06M
End period cash flow 101.97M 99.85M 281.26M 95.78M 178.74M
Total cash from operating activities -240.11M -126.23M 1.88M -65.00M -50.10M
Issuance of capital stock 173.44M 163.31M 226.17M 108.48M 216.82M
Depreciation 2.31M 1.54M 0.46M 2.45M 2.77M
Other cashflows from investing activities 4.83M 5.95M - - -
Change to inventory 0.49M 1.60M -1.55M -0.76M 1.35M
Change to account receivables -10.67M -0.24M 14.43M -2.66M -10.60M
Sale purchase of stock - - -0.17M -0.29M -0.15M
Other cashflows from financing activities -1.39M 0.81M -1.97M 7.98M 0.22M
Change to netincome - - - 38.38M 6.66M
Capital expenditures 3.28M 4.05M 3.48M 2.15M 0.16M
Change receivables - - - -2.66M -10.60M
Cash flows other operating - - - -1.36M -0.33M
Cash and cash equivalents changes - - - -82.96M 133.68M
Change in working capital -33.78M -27.77M 58.88M -3.02M -1.74M
Stock based compensation 27.87M 36.74M 12.06M 14.18M 7.45M
Other non cash items -4.83M -5.95M 1.18M 23.65M 0.63M
Free cash flow -243.39M -130.28M -1.61M -67.16M -50.25M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EYPT
EyePoint, Inc		 0.00
0.03%		 0.36 - 6.16 110.06 2.20 73.80 11.56
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

EyePoint, Inc

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

480 Pleasant Street, Watertown, MA, United States, 02472

617 926 5000

https://eyepoint.bio

214

Name Title Year Born
Ms. Nancy S. Lurker Pres, CEO & Director 1957
Mr. George O. Elston Chief Financial Officer 1965
Dr. Jay S. Duker M.D. Chief Operating Officer 1959
Mr. David Scott Jones Sr. VP & Chief Commercial Officer 1967
Mr. Said Saim Chief Technology Officer 1958
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Sec. NA
Mr. Michael Pine Chief Corp. Devel. & Strategy Officer 1976
Ms. Jennifer Leonard Chief People Officer & Sr. VP of IT NA
Dr. Dario A. Paggiarino Sr. VP & Chief Medical Officer 1957
Ms. Isabelle Lefebvre Chief Regulatory Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…